Analyzing Psychological Disorders Essay Example for Free

Analyzing Psychological Disorders Essay A psychiatric or psychological disorder is a disorder of psychological function severe enough to warrant treatment by a psychiatrist or clinical psychologist. Schizophrenia, emotional disorders, Anxiety and Tourette’s syndrome are all classified as psychiatric disorders. The distinguishing line between neuropsychological disorders and psychiatric disorders is quite thin. Though the two types of disorders are a result of a dysfunctional brain, the malfunctions which create psychiatric disorders remain undefined. Psychiatric disorders are often linked to environmental factors as well as dysfunction of the brain. As psychological research advances, treatments and a better understanding of psychiatric disorders comes to bear. The term schizophrenia means a psychic break or â€Å"splitting of psychic function†. (Pinel, 2007). The NIH National Library of Medicine web site defines schizophrenia as having five different categories: catatonic, disorganized, paranoid, residual, and undifferentiated. (NIH National Library of Medicine, 2008). Each category of the disorder has a specific set of symptoms that is mostly unique to that category of the disorder, but schizophrenia in general creates a delusional picture of reality which disrupts the person’s behavior, logic and emotions. A good example of schizophrenia and the related dissociative disorders are the movie Sybil or the more recent film A Beautiful Mind, and another fine example is the television show United States of Tara. Both movies and the Showtime network’s series depict the lives of a person suffering with schizophrenia or dissociative disorders. Neuroleptics and antipsychotic drugs are known to alleviate symptoms associated with schizophrenia. Clozapine is a type of neuroleptic that does not produce side effects like those associated with Parkinsons disease. The medication is known to cause blood disorders. Neuroleptic medication is used to block the dopamine receptors though it takes time for the drug to lessen schizophrenic symptoms. Though neuroleptics help schizophrenics, only certain patients do benefit from the relief these drugs can offer. Schizophrenic patients suffering from hallucinations and incoherence react to the medication; however; schizophrenics suffering from cognitive defects are not affected. The NIH National Library of Medicine web site mentioned atypical antipsychotics have proven to treat symptoms for schizophrenia  with few side effects and is the best option for those suffering with schizophrenia. (NIH National Library of Medicine, 2008). A surgeon in the 1950’s and early 1960’s used a drug called chlorpromazine on patients to alleviate swelling prior to surgery. The doctor noticed that the medicine acted as a calming agent and recommended chlorpromazine to relax hard to control psychotic patients. Chlorpromazine did not assuage the symptoms of psychosis, but the medicine showed potential for easing some symptoms in schizophrenic patients. During the research process the side effects of chlorpromazine which are symptoms of Parkinsons disease were evident. Researchers concluded that people suffering from Parkinsons disease die from a minute level of dopamine. Schizophrenics display a high-level of dopamine. Therefore Parkinsons and Schizophrenia seem to be on the opposite end of the spectrum. A breakthrough emerged in the dopamine theory with Carlsson and Lindqvist. The duo studied the Chlorpromazine in relation to schizophrenia and revised the dopamine theory of schizophrenia. Chlorpromazine was found to block dopamine receptors instead of the original theory of reducing dopamine levels. Therefore, the duo concluded through research that schizophrenia was  not due to high-levels of dopamine, but with over activity at the dopamine receptors. (Pinel, 2007). Emotional disorders are another form of a psychiatric disorder. Emotional disorders include: bipolar disorder, depression, and mania. Depression is classified as a state of unbearable sadness. At some point in a persons life one will encounter a period of depression due to a tragedy such as loss of a loved one, poor health, or a series of bad luck. However, most people will break through the grip of depression and return to a normal life. Those with depression have a hard time seeing anything in a positive light. Depression ruins relationships at work and in the home; the disease also takes over the person making it difficult to engage in a normal day-to-day routine. Mania is the opposite of depression and is linked to high energy and impulse. A person suffering from mania appears to be full of energy or â€Å"hopped up† on energy drinks like Red-Bull and caffeine; they are filled with such enthusiasm, have boundless energy and talk fast. Though it sounds like an exceptional  thing to be constantly in a good spirits there is a negative side to the disorder. Impulsiveness is a part of mania and many suffers act on impulse not thinking before they do anything. The end result is unfinished projects, bills that cannot be paid, and relationships ruined. A person who suffers from manic episodes and depression episodes is diagnosed with bipolar disorder. There are two theories created to explain the causes of emotional disorders. According to Pinel (2007), The monoamine theory of depression holds that depression is associated with under-activity at serotonergic and noradrenergic synapses. It is based on the fact that monoamine oxidase inhibitors, tricyclic antidepressants, selective serotonin-reuptake inhibitors, and selective norepinephrinereuptake inhibitors are all agonists  of serotonin, norepinephrine, or both. The second theory is Diathesis-Stress model. The second theory focuses on genetic predispositions of a person as well as environmental factors that influence the disorder. This means that people who have stress early on will overreact to stressful situations later in life in turn causing depression. (Pinel, 2007). There are four types of medicine used to treat emotional disorders. Iproniazid is a Monoamine Oxidase Inhibitor (MAOI) initially used to treat tuberculosis but failed. On the contrary the patients did not have as many depressive thoughts about the illness. Iproniazid has severe effects when combined with tyramine rich foods. Imipamine is a tricyclic antidepressant which has proven to be more effective than MAOI’s. The next medication is Lithium which was shown to alleviate symptoms of mania. The discovery was made when a researcher tested guinea pigs and the results proved to calm them. Lithium is used as a mood stabilizer in bi-polar patients since it blocks the patient from transitioning between extreme highs and lows. The fourth medicine used more commonly in recent years is selective serotonin-reuptake inhibitors (SSRIs). The most common of the SSRI’s are Prozac, Zoloft and Paxil. The SSRI’s are reported to have few side effects and are able to treat multiple disorders. (Pinel, 2007). Anxiety is chronic fear that persists in the absence of any direct threat. (Pinel, 2007). Anxiety is accompanied by rapid heartbeat, heavy or difficulty breathing and high blood pressure. There are five  types of anxiety disorders including: general anxiety, phobias, obsessive compulsiveness, panic, and post traumatic stress disorder. Theories involving anxiety disorders presume the amygdala has a role in anxiety disorders. The brain’s involvement in anxiety is cloudy at best since each patient tested shows different results. (Pinel, 2007). Benzodiazepines and serotonin agonists are the most effective medications used to combat anxiety. Valium and Librium are two of the most commonly prescribed medications, though they tend to make the patient drowsy. The medicine is  also known to be highly addictive and is recommended only for short-term usage. Buspirone is a serotonin agonist which relaxes the body and causes sleepiness. (Pinel, 2007). Tourette’s syndrome is known for involuntary movements or sounds known as tics. The Cedars-Sinai web site notes that the tics can vary from body movements and vocal tics. The tics can be a little as involuntary eye blinking or more noticeable yelling of obscene words or phrases. Little is known as to the cause of Tourette’s, however there is speculation that the limbic cortex, association cortex and thalamus are connected to the disorder. (Pinel, 2007). With the cause still a mystery there is no cure for Tourette’s, but though counseling, relaxation therapy and hypnosis healthcare professionals can help treat the disorder. (Cedars-Sinai. 2008). Psychiatric disorders vary in many ways. Schizophrenia affects the brain and causes hallucinations, emotional disorders affect a persons mood in extreme ways, and anxiety causes fear and health issues, while Tourette’s causes tics ranging from subtle to severe. Over time psychological advances in research and treatment have been made allowing professionals in the field to effectively treat each disorder. References CEDARS-SINAI. (2008). Tourettes syndrome. Retrieved June 10, 2009, from http://www.csmc.edu/5540.html NIH National Library of Medicine. (2008). Medical Encyclopedia: Schizophrenia. Retrieved June 9, 2009, from http://www.nlm.nih.gov/medlineplus/ency/article/000928.htm Pinel, J. P. J. (2007). Basics of Biopsychology. Boston, MA. Allyn and Bacon.

Tibetan Medicine Essay -- Tibet Treatment History Illness Papers

Tibetan Medicine Tibetan medicine, developed over the course of over one thousand years in the isolated mountainous terrain of Tibet and preserved despite China’s decimation of Tibetan customs, views healing in a much different way than Western physicians. Tibetan medicine emphasizes science, faith, perception, spirituality, karma, and philosophy, whereas Western medicine is based almost entirely on science. In the West, religion and spirituality are believed to have absolutely nothing to do with healing and medical practice. Without looking at Tibetan medicine in depth, the Westerner could easily dismiss Tibetan medicine as superstitious and unscientific; however, Tibetan Medicine is often very successful at treating illness, and Tibetan physicians can often cure the root of the problem, rather than merely performing a quick fix to a localized part of the body as in the West. Tibetan doctors do not recommend simply popping a pill. Instead, they see illness as a manifestation of the body†™s imbalance and seek to correct this imbalance. In order to cure a disease, behavior, lifestyle, and one’s individual ‘humoral constitution’ (the three humors and the way in which they function in the body will be fully explained later) are all very important. In order to gain a fuller understanding of the Tibetan approach, as well as appreciate why it has remained so unknown to Westerners despite its lengthy existence, one must consider the Tibetan and Western medical traditions simultaneously. One is also inclined to consider if aspects or methods of diagnoses from the Tibetan tradition could be incorporated into Western medicine since each form of practice has own benefits – Western medicine has highly sophisticated technology and the... ...he Source, 131. [8] John Avedon, In Exile from the Land of Snows, 156. [9] Vaidya Dash, Tibetan Medicine, 86. [10] Vaidya Dash, Tibetan Medicine, 87. [11] Vaidya Dash, Tibetan Medicine, 89. [12] Dr. Yeshi Dhonden. Health Through Balance. (Ithaca, NY: Snow Lion Publications, 1986), 142. [13] Dr. Dhoden, Health Through Balance, 148. [14] Dr. Dhonden, Healing from the Source, 129. [15] Christopher Hansard, The Tibetan Art of Living, (New York: Atria Books, 2001), 191. [16] Christopher Hansard, The Tibetan Art of Living, 193. [17] Christopher Hansard, The Tibetan Art of Living, 193. [18] Dr. Dhonden, Health Through Balance, 185. [19] Dr. Dhonden, Health Through Balance, 216. [20] Dr. Dhonden, Healing from the Source, 187. [21] Dr. Dhonden, Healing from the Source, 187. [22] John Avedon, In Exile from the Land of Snows, 155.

Pfizer Strageic Plan

OUTLINE FOR THE STRATEGIC PLAN Please bullet your responses. Staple the completed assignment; do not spend any money binding the assignment. Make sure to respond to every item. I. GETTING STARTED A. Steps in Strategic Management Process Step 1 |Identify the organization’s mission, vision, and value statement | |Step 2 |Determine the firms main business and organizational objectives | |Step 3 |Conduct a SWOT analysis identifying the company’s strengths, weaknesses, opportunities, and threats | |Step 4 |Construct a Competitive Profile Matrix (CPM) | |Step 5 |Construct an External Factor Evaluation (EFE) Matrix | |Step 6 |Construct and Internal Factor Evaluation (IFE) Matrix | |Step 7 |Construct a Value Chain Analysis | |Step 8 |Prepare a SPACE, BCG, TOWS Analysis, and QSPM Matrix | |Step 9 |Use the data above to weigh alternative strategies, make strategic recommendations, develop a plan of action | | |(implementation), and convey the ROI | |Step 10 |Construct Conting ency Plan | B. Information and/or materials used to complete assignment †¢ Resources used in completing the assignment are as follows: Strategic Management Concepts and Cases’ 12th edition textbook, S&P 500 website, Yahoo Finance, Bloomberg. com, Pfizer. com, Google Finance, Reuters. om, and Google search engine including the web pages cited on the Works Cited page. C. Time Frame †¢ My goal is to actively work on a portion of the outline everyday and have it completed to its entirety by the time it is due; therefore I will not have to rush to get it done last minute. D. Resources Needed – all resource your team used to complete this assignment †¢ FAMU database, online articles, company website. II. MANDATES (â€Å"MUSTS†) -CLARIFYING/UNDERSTANDING A. History/Evolution of the Organization †¢ Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York and has remained dedicated to improving the health and well being o f individuals around the world.The demand for Pfizer’s products soared throughout the Civil War as the demand for painkillers, disinfectants and preservatives increased. In 2000, Pfizer and Warner-Lambert merge to form the new Pfizer, which created the world’s fastest growing Pharmaceutical company. In 2008, Jeff Kindler, Chairman and CEO of Pfizer, announces the next step in the company's evolution and outlines the company's plan to establish smaller operating units designed to enhance innovation and accountability, while drawing upon the advantages of Pfizer's scale and resources. On October 15, 2009, Pfizer acquires Wyeth, creating a company with a broad range of products and therapies that touch the lives of patients and consumers every day and at every stage of life.In 2010, Pfizer announces a diversified R platform named Pfizer Worldwide Research and Development, supporting excellence in small molecules, large molecules and vaccine research and development. As ap art of the acquisition of Wyeth in 2009, Pfizer initially implemented a two-division structure for research and development (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. Due to the speed and effectiveness of that integration, Pfizer progresses to this new model while maintaining the same breadth and research programs. On December 1 and 2 2011 Pfizer completed the acquisitions of Excaliard Pharmaceuticals and Ferrosan Consumer Health’s Business, respectively. B.Identify formal aspects of the organization †¢ Corporate Governance Include: Board of Directors, Board Committees, Code of Ethics, CEO/CFO Certifications, Executive Officers, Policy and Procedures for Accounting and Legal Complaints †¢ Pfizer has created two distinct research organizations. The PharmaTherapeutics Research & Development Group focuses on the discovery of small molecules and related modalities; and The BioTherapeutics Research & Development Group focuses on large-molecule research, including vaccines. The goal with Pfizer doing this is to maximize opportunities within the Biomedical research sector. †¢ Pfizer has also developed an enhanced commercial operating structure.Pfizer has nine diverse health care businesses: Primary Care, Specialty Care, Oncology, Emerging Markets, Established Products, Consumer Healthcare, Nutrition, Animal Health and Capsugel. Each of these businesses is led by an executive with clear accountability for results – from product development following proof of concept to providing access to patients and through to the end of the product's life cycle. B. Identify informal aspects & culture of the organization †¢ Pfizer is sustained on innovation, which seeks a nourishing environment in which ideas and perspectives can flourish. It is an array of unique characteristics, perspectives, and life experiences. Pfizer Colleague Resource Groups (CRGs) are organized by coll eagues who join together to provide a positive forum for professional development. By embracing diversity of thought and experience, our CRGs help drive innovation and build on our success. †¢ David Simmons, the president and general manager of the Established Products Business Unit at Pfizer. Simmons has been highly successful at building a new, non-traditional culture within Pfizer for his business unit. One example of this was that Simmons was able to product high quality drugs at affordable costs, and he did this as high grossing patents were near expiration III. VISION STATEMENT, MISSION STATEMENT & VALUES STATEMENT ANALYSES A. Vision StatementAt Pfizer, we're inspired by a single goal: your health. That's why we're dedicated to developing new, safe medicines to prevent and treat the world's most serious diseases. And why we are making them available to the people who need them most. We believe that from progress comes hope and the promise of a healthier world. B. Vision S tatement Analysis – Does it answer the question â€Å"What to do we want to become? † If not, revise it. If organization does not have one, create one. †¢ Yes, I believe that it answers the question as to what they want to become. Its states that they are dedicated to developing new ways to prevent and treat diseases. C. Values Statement Pfizer does not have a value statement. D. Value Statement Analysis – Does it represent the organization’s guiding principles? If not, revise it. If organization does not have one, create one. †¢ Pfizer will work to provide the best quality drugs that will cater to the most people. We will ensure that as a company we will work to do what is best for our patients, physicians and consumers. B. Mission Statement †¢ We will become the world's most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. D. Mission Statement Analysis – Do es it have the 9 components? If not, revise it to include all 9 components.If organization does not have one, create one. †¢ No, the mission statement does not include all the nine components. After revising the mission statement, it should be read: o We will become the world’s most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. We will ensure that we provide products of the best quality at affordable prices to all. We will work hard to ensure that we keep up with the needs and problems of our consumers and provide what is best. We will continue to promote the well-being of our consumers as well as the well-being of our shareholders and employees as well as promote diversity.We will keep abreast of the ever-changing technology to ensure that they needs of our consumers are met at all times and also that we will not become obsolete to our customers. We will forever be dedicated to developing new , safe medicines to prevent and treat the world's most serious diseases. And why we are making them available to the people who need them most. |List each of the 9 components |Excerpts from Mission Statement addressing the component | |1. Customers |We will work hard to ensure that we keep up with the needs and problems of our consumers and provide what is| | |best. | |2.Products or Services |We will ensure that we provide products of the best quality at affordable prices to all. | |3. Markets |We will ensure that we provide products of the best quality at affordable prices to all. | |4. Technology |We will keep abreast of the ever-changing technology to ensure that they needs of our consumers are met at | | |all times and also that we will not become obsolete to our customers. | |5. Concern for survival, growth, and profitability|We will keep abreast of the ever-changing technology to ensure that they needs of our consumers re met at | | |all times and also that we will not become obsolete to our customers. | |6. Philosophy |We will forever be dedicated to developing new, safe medicines to prevent and treat the world's most serious| | |diseases. And why we are making them available to the people who need them most. | |7. Self- Concept |We will become the world’s most valued company to patients, customers, colleagues, investors, business | | |partners, and the communities where we work and live. | |8.Concern for public image |We will continue to promote the well-being of our consumers as well as the well-being of our shareholders | | |and employees as well as promote diversity. | |9. Concern for employees |We will become the world’s most valued company to patients, customers, colleagues, investors, business | | |partners, and the communities where we work and live. | IV. ASSESSING EXTERNAL ENVIRONMENT A. Identify Opportunities / Threats – Analyze trends in the following areas: political, legal, competitive, economic, social, cultural, demo graphic, technological, environmental, and governmental. Provide at least 1 opportunity & 1 threat for each of the 10 areas. Provide responses in bullet format. Political | |Opportunity |Threat | |Measures taken to close the Coverage gap also known as the donut hole may |New Health care Reform Bill was put in place 2010. This law requires drug | |result in people using more brand name drugs rather than buying generic. 9 |producers to make rebates to state Medicaid agencies based on their costs to | | |provide prescription drugs to Medicaid beneficiaries. | | |Constant pressure to lower prescription drug prices from the government2 | |Legal | |Opportunity |Threat | |Acquisitions and in-licensing /co-development opportunities such as recent |Expiration of Patents for drugs, face a loss of up to billions of dollars due | |acquisitions of Excaliard and Ferrosan Consumer Health’s Business in December |to generics taking market share.For example, Lipitor, which grossed 11 bil lion| |2011 may help Pfizer meet unmet needs of their customers. 23 |in revenues last year expired November 28, 2011. This means that other | | |companies are allowed to produce the generic version of the drug. 2 | | |Number of New Molecular Entities approved by the FDA has declined. In 2009, | | |NMEs approved were 26 and 2010 were 21. 2 | | |Beginning of 2011 was a series of new fees in the form of excise taxes payable | | |to the federal government. 12 | |Competitive | |Opportunity |Threat | |Barriers for additional companies to enter the market are high. 4 |French drug maker Sanofi-Aventis’ $20 billion acquisition of Genzyme Corp. | | |completed in April 2011 | | |Fierce competition among Pharmaceutical companies such as Proctor & Gamble and | | |Johnson & Johnson. | | |Japanese drug sales are also expected to expand with current sales of 60 | | |billion, 11% of the world market share. | |Economic | |Opportunity |Threat | |Demands for certain drugs are relatively in elastic. 4 |Based on the projected losses due to loss of market share, Pfizer has shed | | |53,000 and 61, 000 jobs in 2010 and 2009 respectively | | |The decline in spending in the US in the last few years | | |Revenue may be hurt by ongoing negative effects from U. S. ealth care reform | | |and austerity pricing in Europe | | |Inflation will cause an increase in cost and raise drug prices | | |Competition from newer, better drugs may be a threat to sales. For example, | | |Vivus is a new ED drug that may be able to compete with Viagra. 3 | |Social | |Opportunity |Threat | |450 million Americans are over the age of 65 and healthcare spending is the |Number of NMEs approved by the FDA has declined12 | |highest among these individuals2 | | |Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for| | |Seniors in 2011. | | |Cultural | |Opportunity |Threat | |Like GlaxoSmithKline and Abbott Labs in particular — Pfizer has its sights on |Number of legis lative proposals seeking to allow importation of medicines into | |developing countries for a revenue bump. 13 |the U. S. and revenues could be affected | |Demographic | |Opportunity |Threat | |Asian drug sales are also expected to expand.For example, Takeda |77 million people by 2031 will be enrolled in Medicare and Health care and | |Pharmaceutical Company, Asia's biggest drug maker, reported an 18 percent jump |Medicare will not be able to finance this many people2 | |in first-quarter profit, helped by the sale of new medicines in the beginning | | |of 2011. 9 | | |Technological | |Opportunity |Threat | |Pfizer has plenty of drugs in its pipeline with blockbuster potential. 3 | | |Environmental | |Opportunity |Threat | |Adoption of new environmental strategies to be more socially responsible |Adverse effect on drug prices due to threat of imported drugs and threat of | | |counterfeited drugs due to importing and exporting. | B. Monitor Major Stakeholders/Stakeholder Analys is – Customers, Competitors (list at least 3 of the organizations major competitors, Individuals in the community, Employees, Stockholders, etc. 1. Identify Stakeholders |Identify Internal Stakeholders |Identify External Stakeholders | |Ian C.Reed- President, CEO, Director |Johnson & Johnson | |Frank A. D’Amelio- CFO, EVP of Business Ops. |JP Morgan Chase & Co | |Mikael Dolsten- Pfizer Worldwide R&D |Northern Trust | |Freda- Lewis Hall- EVP, Chief Medical Officer |Proctor & Gamble | 2. Stakeholder Matrix – classify the internal & external stakeholders identified above into the appropriate boxes. High Interest/Importance, High Influence |High Interest/Importance, Low Influence | |Ian Reed |Proctor & Gamble | |Frank D’Amelio |Johnson & Johnson | |JP Morgan Chase & Co |Dow Chemical | |State Street Corporation |Merck and Co Inc. | | |Customers | | Employees | |Low Interest/Importance, High Influence |Low Interest/Importance, Low Influence | |Governme nt |Lenders | |Insurance Companies |Suppliers | | | | | | | | | | 3. Stakeholder Analysis |Stakeholder |Responsibility of |What does organization |Stakeholder’s potential |Stakeholders’ perceived |Stakeholder Management | | |Stakeholder to the |expect the stakeholder to |impact on the organization |attitudes and/or risks to |Strategy (SMS) | | |organization |provide? (high, medium, or low) |the organization | | | | | | | |N/A | |Investors |Fund the organization |Provide funding and |High |High Risk; Conservative | | | | |liquidity to the | |Attitude | | | | |organization | | | | | |Strategic plans and |Provide expertise, | |High Risk; Positive |Bottom-Up | |Employees |operations.Supports the|knowledge and value |High |Attitude | | | |functionality and | | | | | | |operational processes | | | | | | |Make critical decisions |Provide conceptual |High |High risk; Conservative |Top-down | |Shareholders | |knowledge and top-down flow| |Attitude | | | | |of decision maki ng | | | | | |Meet market demands |Provide products and | |Medium Risk; Positive |N/A | |Suppliers | |services |Medium |Attitude | | External Factor Evaluation |Opportunities | | | | | |Weight |Rating (1-4) |Weighted Score | |1. Measures taken to close the donut hole may result in people using more brand |. 07 |3 |. 1 | |name drugs rather than buying generic | | | | |2. Acquisitions and in-licensing /co-development opportunities |. 06 |4 |. 24 | |3. 450 million Americans are over the age of 65 and healthcare spending is the |. 07 |4 |. 28 | |highest among these individuals | | | | |4. Expansion of the biologic pharmacy market. |. 07 |4 |. 28 | |5. Bought King pharmaceutical for $3. 6 billion which would open up more |. 06 |4 |. 4 | |manufacture and sales adding to the capital of the company (Carrie, 2009). | | | | |6. Barriers for additional companies to enter into market are high |. 05 |4 |. 20 | |7. Demands for certain drugs are relatively inelastic. |. 07 |4 |. 28 | |Threats | | | | |8. Japanese drug sales are also expected to expand with current sales of 60 |. 08 |2 |. 6 | |billion, 11% of the world market share. | | | | |9. In 2009, Pfizer got assessed a 2. 3 billion fine for which they employed illegal|. 08 |1 |. 08 | |marketing strategies. | | | | |10. Large manufacture and low research for new inductions in the market could |. 07 |2 |. 14 | |decline the profitability. | | | | |11. Constant pressure to lower prescription drug prices from the government |. 5 |2 |. 1 | |12. Number of NMEs approved by the FDA has declined |. 04 |2 |. 08 | |13. The decline in spending in the US in the last few years |. 07 |1 |. 07 | |14. Inflation will cause an increase in cost and raise drug prices |. 06 |1 |. 06 | |15. Number of legislative proposals seeking to allow importation of medicines into|. 05 |2 |. 1 | |the U. S. nd revenues could be affected | | | | |16. 77 million people by 2031 will be enrolled in Medicare and Health care and |. 06 |2 |. 12 | |Medicare will not be able to finance this many people | | | | | | |Total |2. 64 | Pfizer seems to be taking advantage of the opportunities presented as well as avoiding threats but there is still room for improvement.For example, Pfizer seems to be taking advantage of some of the acquisitions that they have had over the last two years. They are seizing the opportunities of the expanding biological pharmacy market. Starting with the acquisition of Wyeth in 2009 and then the acquisitions of Excaliard and Ferrosan Consumer Health’s Business. Pfizer saw that they were not meeting the needs of some of their customers but their competitors were. Excaliard is a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. Ferrosan Consumer Health’s Business focuses on dietary supplements and lifestyle products.In addition to this, although New Molecular Entities approved by the FDA have declined, Pfizer has managed to get 3 drugs approved by the FDA in 2011 alone. Lastly, Pfizer has responded relatively well to the governmental pressure of lowering their prices as well as the Lipitor patent expiring at the end of November. Pfizer has implemented multiple rebate and discount programs to help assist their consumers. For example, Pfizer has recently partnered with Wal-Mart to offer a $4 prescription program allowing consumers to obtain their prescriptions at that low price. This helps to mitigate the complete loss of revenue and market share if consumers were to go to generic all together.I believe that the reason Pfizer did not receive a score of higher than a 3 was because a lot of these new policies have been recent (2010, 2011) and Pfizer seems to be trying to figure out how to remain profitable as well as cater to their consumers and these acquisitions are all relatively new and Pfizer seems to be just getting adjusted. Competitive Profile Matrix | |Pfizer |Johnson & Joh nson |Eli Lilly | |Critical Success Factors |Weight |Rating |Weighted Score |Rating |Weighted |Rating |Weighted Score | | | | | | |Score | | | |Organizational Structure |. 05 |2 |. 10 |4 |. 20 |1 |. 5 | |Price Competitiveness |. 10 |3 |. 30 |3 |. 30 |3 |. 30 | |Advertising |. 04 |1 |. 04 |1 |. 04 |4 |. 16 | |Product Quality |. 10 |3 |. 30 |3 |. 30 |3 |. 30 | |Sales Distribution |. 10 |4 |. 40 |3 |. 30 |2 |. 0 | |Customer Loyalty |. 03 |3 |. 09 |3 |. 09 |3 |. 09 | |Global Expansion |. 11 |4 |. 44 |3 |. 33 |2 |. 22 | |Market Share |. 11 |4 |. 44 |4 |. 44 |3 |. 33 | |Demographics |. 03 |3 |. 09 |3 |. 09 |3 |. 9 | |Financial Position |. 15 |4 |. 60 |3 |. 45 |2 |. 30 | |Research and Development |. 13 |4 |. 52 |4 |. 52 |3 |. 39 | |Innovation |. 10 |3 |. 30 |3 |. 30 |2 |. 20 | |Total |1. 00 | |3. 52 | |3. 16 | |2. 58 |From constructing the Competitive Profile Matrix, it is apparent that Pfizer is the strongest among the three competitors compared. V. ASSESSING INTERNAL ENVIRONMENT A. Stren gths/Weaknesses |Management | |Strength |Weakness | |In June 2011, Pfizer announced strategic partnerships with ICON plc and PAREXEL|Sometimes Pfizer may have to discontinue the production of drugs; therefore the| |International Corporation, both of which will serve as strategic providers of |demand for that drug increases. |clinical trial implementation services over a five-year period beginning in | | |June 2011 | | |Adoption of new environmental strategies to be more socially responsible | | |Working with numerous companies to do collaborative work in research and | | |development. | | |Pfizer is continually developing new strategies such as plant restructuring and| | |energy master plan. | |Pfizer is divided into multiple sectors so that most leaders have a specific | | |rather than general role. | | |Pfizer expects to increase its market share from 4% to 6% by reinforcing its | | |leadership, expanding developments in high growth markets, building leadership | | |in oncology and taking advantage of R&D in Asia and other countries. | |Marketing | |Strength |Weakness | |Renewed emphasis in the faster growing fields of specialty pharmaceuticals, |Co marketing with other pharmaceutical companies may slow down its global | |biologics, vaccines, and, in some cases, even generics. |growth. | |Its number one pharmaceutical from sales point of view and its marketing |Decreased amount of advertising | |infrastructure is well established throughout the world. | | |Pfizer as six markets, which include Brazil, China, Mexico, Turkey, Russia, and| | |India. | |For the ninth consecutive year, the Pfizer Pharmaceutical Sales Force was voted| | |as first overall in Verispan's â€Å"Pharmaceutical Sales Force Structures. | | |Human Resources | |Strength |Weakness | |Global working network with 95,000 workers |According the glassdoor. om, the company morale is at an all time low | |Accounting/Financials | |Strength |Weakness | |7. 5% ranking corporation market share | Prices, according to the federal government, are too high and are currently | |Sales have increased from 16. 02% in 2008 to 22. 89% in 2010. |trying to get Pfizer to cut their prices. | |High budget pharmaceutical industries having the revenue of $50 billion |Lowest Earnings per Share among competitors. For example, Pfizer has an EPS of | | |$. 48 and Johnson & Johnson and Eli Lilly have an EPS of $1. 5 and $1. 11, | | |respectively. | | |The integration of large acquisitions including a pair by Pfizer — hasn’t | | |resulted in s great return on equity. | | |Each new drug can cost as much as $1 billion to develop, with no guarantee of | | |success. |Internal Technology | |Strength |Weakness | |Due to the expectation of the drugs expiring and the decline and market share, |Delays caused by regulations and the unsuccessful completion of clinical trials| |Pfizer has focused most of the R&D on Biotech based treatments |reduce the potential recovery and returns of investme nts such as R&D. | |Their research and development sector is highly established and in good | | |strength. | | |Renewed emphasis in the faster growing fields of specialty pharmaceuticals, | | |biologics, vaccines, and, in some cases, even generics. | | |Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc.For The | | |Development And Commercialization Of Neratinib, An Investigational Pan-HER | | |Inhibitor | | |U. S. Food And Drug Administration Approves Pfizer’s XALKORI ® (crizotinib) As | | |First And Only Therapy Specifically For Patients With Locally Advanced Or | | |Metastatic ALK-Positive Non-Small Cell Lung Cancer. | | | | |Other | |Strength |Weakness | |Chance to acquire new patents for new technological products |Currently only serving American, European and Asian markets. They are not | |Pfizer has been public in its efforts to address climate change. Our Energy and|serving African or Australian markets. | |Climate Change Program seeks to minimize the cost and operational restrictions | | |arising from a carbon-constrained environment, reduce Pfizer's contribution to | | |GHG emissions, and assess the risk presented to Pfizer's operations from the | | |potential physical changes resulting from a warming global climate. | |Pfizer has committed to ensure that their quality is top notch and no | | |counterfeit products have been purchased by their consumers. | | |Pfizer is committed to its outsourcing. The key considerations for outsourcing | | |decisions include the ability to supply and capacity flexibility, regulatory | | |compliance and safe practices, technology and cost competiveness. | | |Pfizer has a structure for quality.Some components include creating, | | |implementing, and upholding standard operating procedures for trial execution, | | |a quality scientific and medical design of the protocol, clinical investigator | | |and site pre-assessment and selection, regulatory agency and ethics committee | | |approval, dev eloping and providing appropriate informed consent, adequate | | |recording and reporting of data, periodic monitoring and audits. | | B. Value Chain Analysis – Graphically depict the organization’s value chain |Infrastructure: | |-Pfizer's Executive Leadership Team is the company's senior-most leadership and decision-making management body. It brings together our top leaders to focus on major | |financial, strategic and operational decisions for the company. | |-The Governance structure of Pfizer consists of an Executive Board (CEO, CFO, President), Board of Directors (Dennis Ausiello, Michael S.Brown), Shareholders (JPMorgan,| |Northern Trust, Ian Reed, State Street Corporation). | |-Pfizer has made several initiatives to ensure a diverse company culture. They also have recognized their responsibility towards their customers. Certain policies | |include: Business conduct, Lobbying and Political contributions, Sales and Marketing, Research and clinical trials, workpl ace standards, and laboratory animal care. 10 | |Human Resource Management: | |Pfizer has agreements with different universities and recruit from different areas of study. This serves to create a diverse environment and fosters a challenging and | |open culture.Some of their values with regards to their employees are: sustain focus on performance, create an inclusive environment, exchange open discussion and | |debate, manage change, develop people, and align across Pfizer. 2 | |Research and Development: | |Pfizer is prioritizing its research and development efforts in areas with the greatest scientific and commercial promise: immunology and inflammation, oncology, | |cardiovascular and metabolic diseases, neuroscience and pain, and vaccines.Through major research efforts across multiple modalities including small molecules, | |biologics and vaccines. | |Pfizer has set up the phases of clinical development from making the drug to administering the drug through clinical trials and then manufacturing and selling the drugs. | |2 | |Procurement: | |Pfizer is expected to increase outsourced manufacturing of products from approximately 17 percent to 30 percent over the next three years. Key considerations for | |outsourcing decisions include the ability to supply, capacity flexibility, cost competitiveness,and technology. | |Inbound Logistics: |Operations: |Outbound Logistics: |Marketing and Sales: |Service: | |Pfizer procurement professionals |-Pfizer has nine diverse health|-Pfizer has trained over 95 |-Channels of marketing include:|-Pfizer is committed to providing a | |regularly |care businesses: Primary Care, |percent of colleagues worldwide|Television, print ad and online|quality drug to their customers. | |engage with suppliers to reinforce |Specialty Care, Oncology, |in basic problem solving, which|ads. Pfizer has created programs such as | |Pfizer’s expectations in all |Emerging Markets, Established |has resulted in over 8,000 |-Pharmaceutical sa les |the $4 Wal-Mart prescription program| |operational business areas. This |Products, Consumer Healthcare, |improvement |representatives are among the |to provide their drugs at a fraction| |collaboration leads |Nutrition, Animal Health and |projects across the world in |top in the nation. They receive|of the cost. | |to improvement projects with |Capsugel†. 8 |the last five |extensive training so they are |- | |significant performance benefits, | |years. Significant improvements|knowledgeable of the drugs. | |such as reduced | |to Pfizer’s |They have knowledge of Pfizer | | |packaging and transportation costs, | |key products have delivered a |products as well as their | | |and elimination of undesirable | |40 percent reduction in both |competitors. 2 | | |chemicals through process | |the time to make and ship the | | | |improvements†. 8 | |product as well as allowing a | | | | | |reduction in inventory†. 8 | | | Primary Activities Financial Ratios: Finan cial Ratios |Pfizer Inc |Industry |S&P 500 |How Pfizer is doing in | | | | | |comparison to the industry? | |Growth Rate % | | | | | |Sales (Qtr vs. year ago Qtr) |7. 5 |5. 90 |14. 40 |Better | |Net Income (YTD vs. YTD) NA |NA |NA | | |Net Income (Qtr vs. year ago Qtr) |185. 10 |66. 00 |46. 30 |Better | |Sales (5 Year Annual Avg) |7. 42 |7. 59 |8. 28 |Worse | |Net Income (5-Year Annual Avg) |1. 68 |2. 38 |8. 48 |Worse | |Dividends (5-Year Annual Avg) |-1. 08 |9. 81 |5. 9 |Worse | | | | | | | |Financial Condition | | | | | |Debt/Equity Ratio |. 46 |1. 14 |1. 05 |Better | |Current Ratio |2. 3 |1. 7 |1. 4 |Better | |Quick Ratio |1. 9 |1. 4 |1. 0 |Better | |Interest Coverage |9. 6 |23. 5 |316. |Worse | | | | | | | |Investment Returns % | | | | | |Return on Equity |11. 4 |30. 0 |26. 3 |Worse | |Return on Assets |5. 2 |8. 8 |8. 9 |Worse | |Return on Capital |6. 1 |11. 7 |11. 9 |Worse | | | | | | |Management Efficiency | | | | | |Income/Employee |91,763 |84,518 |130,228 |Better | |Re venue/Employee |616,998 |539,073 |1 Mil |Better | |Receivable Turnover |4. 5 |5. 5 |15. 9 |Worse | |Assets Turnover |0. 4 |0. 6 |0. |Better | |Inventory Turnover |1. 8 |2. 7 |12. 5 |Worse | * http://moneycentral. msn. com/investor/invsub/results/compare. asp? symbol=pfe* C. Assess all Functional areas using the internal checklists Management Audit Checklist – Give an example for each response |1. Does the organization use strategic management concepts? |Yes, Pfizer is continually developing new strategies such as plant restructuring and | | |energy master plan.For example, In June 2011, Pfizer announced strategic partnerships | | |with ICON plc and PAREXEL International Corporation, both of which will serve as strategic| | |providers of clinical trial implementation services over a five-year period beginning in | | |June 2011 | |2. Are organization objectives and goals measurable and well |Yes, some of Pfizer’s goals include maximizing opportunities in Biomedical res earch, | |communicated? |forging relationships with ey customers, etc. | |3. Do managers at all hierarchical levels plan effectively? |Yes, Pfizer is divided into multiple sectors so that most leaders have a specific rather | | |than general role. Pfizer is divided into 2 sectors, the PharmaTherapeutics Research & | | |Development Group and the BioTherapeutics Research & Development Group. Each sector has | | |its own managers; therefore it becomes easier to be able to plan effectively. | |4.Is the organization’s structure appropriate? |Yes, their leadership brings together top leaders to focus on major financial, operational| | |and strategic decisions. They have managers for every sector who work specifically to | | |foster the success of that sector. This creates an atmosphere for managers and employees | | |to focus on their specific sector rather than divide their attention. | |5. Are job descriptions and job specifications clear? Yes, Pfizer provides a detailed descript ion of the top managers and what they do as well | | |as what they expect from all their employees. | |6. Is employee morale high? |No, according to glassdoor. com, the employee morale is at an all time low. | |7. Is employee turnover and absenteeism low? |Yes, Pfizer currently has over 110,000 employees and they have managed to maintain their | | |staff turnover at a rate lower than 10% per year for the past 10 years, despite the | | |industry's average rate of 15%. | |8.Are organizational reward and control mechanisms effective? |Yes, Pfizer has recently raised its salary for its employees from the 50th to the 75th | | |percentile of markets rates. | Marketing Audit Checklist – Give an example for each response |1. Are markets segmented effectively? |Yes, Pfizer as six markets which include Brazil, China, Mexico, Turkey, Russia, and India | |2. Is the organization positioned well among competitors? |Yes, Pfizer ranks #2 right behind Proctor and Gamble | |3. Has the organiza tion’s market share been increasing? Yes, Pfizer expects to increase its market share from 4% to 6% by reinforcing its | | |leadership, expanding developments in high growth markets, building leadership in oncology| | |and taking advantage of R&D in Asia and other countries. | |4. Are present channels of distribution reliable and |No, according to Pfizer. com, globalization has made channels of distribution easy targets | |cost-effective? |for counterfeiting products. Drug Importation also poses a difficult task of closely | | |monitoring these drugs to prevent counterfeiting and damaged goods. | |5. Does the organization have an effective sales organization? Yes, For the ninth consecutive year, the Pfizer Pharmaceutical Sales Force was voted as | | |first overall in Verispan's â€Å"Pharmaceutical Sales Force Structures. | |6. Does the organization conduct market research? |Yes, this is the basis for their business. They have to research the causes and effects | | |for the drugs that they manufacture and produce. | |7. Are the organization’s products and services priced |No, the federal government has been trying to get Pfizer to decrease its prices to be more| |appropriately? |affordable for customers. | |8.Does the organization have an effective promotion, advertising,|Yes, Pfizer products have become a household name for most. Pfizer has a marketing | |and publicity strategy? |strength in major geographical and therapeutic areas. | |9. Is marketing planning and budgeting effective? |Yes, one of Pfizer’s plans is to cut the budget of R by 12 million dollars by the end of| | |2012. | |10. Do the organization’s marketing managers have adequate |Yes, from inspection of the top marketing managers, they all have experience prior to | |experience and training? |Pfizer. | |11.Are product quality and customer service good? |Yes, Pfizer has committed to ensure that their quality is top notch and no counterfeit | | |products have been pur chased by their consumers. They have implemented numerous plans in | | |order to assure top quality. This stems from their procurement strategies such as making | | |sure that their suppliers only produce the utmost quality of products. | Finance Audit Checklist – Give an example for each response |1.Where is the organization financially strong & weak as |Yes, the company has a high gross profit margin at 81. 5%, which indicates a strong | |indicated by financial ratio analyses? |position in the market. | |2. Can the organization raise needed short-term capital? |Yes, their operating activity ratios for the most part have improved. For example, their | | |inventory turnover decreased in 2009 to 4. 03 but then increased in 2010 to 8. 07. | |3. Can the organization raise needed long-term capital through |Yes, most of the company’s ratios seemed to have decreased in 2009, but most recuperated | |debt and/or equity? |in 2010. For xample, total asset turnover decreased in 2 009 to 0. 23 but then increased in| | |2010 to 0. 35. | |4. Does the organization have sufficient working capital? |Yes, the company’s working capital increased since 2009. In 2010, the working capital was | | |$18,991 million. | |5. Are capital budgeting procedures effective? |Yes, the company has decided to cut back in R costs in order to save capital | |6. Are dividend payout policies reasonable? |No, the payout for dividends is currently $. 20 per share which is $. 3 less than its | | |number one competitor, Proctor & Gamble | |7. Does the organization have good relations with its investors |Yes, all the financials are reported online and there is a sense of transparency with the | |and stockholders? |investors and the company. | |8. Are the organization’s financial managers experienced and well |Yes, all managers have experience prior to working at Pfizer | |trained? | | R Audit Checklist – Give an example for each response |1.Does the organization have R facilities? Are they adequate? |Yes, Pfizer has the world’s largest research. Pfizer has six main research locations, | | |which include: New York, California, Massachusetts, Connecticut, UK and Missouri. | |2. If outside R organizations are used, are they cost-effective? |N/A, Pfizer does not use outside R organizations. | |3. Are the organization’s R personnel well qualified? |Yes, Pfizer has a rigorous screening process for their scientists that work in R. This | | |is done to ensure a quality product. | |4. Are management information and computer systems adequate? Yes, Pfizer engaged PA Consulting Group to create and implement a rapid, insightful | | |information management solution that would help the company manage and derive value from | | |the wealth of project and agreement information. 14 | |5. Is communication between R and other organizational units |Yes, communication has to be effective when it comes to R and the other sectors. This | |effective? |has to be done to ensure safe, effective products. | |6. Are present products technologically competitive? |Yes, Pfizer has some of the leading medications in areas such as Internal Medicine.The | | |drug Lipitor is the leading drug for the reduction of cholesterol in the industry as of | |

The Importance of Being Earnest Play/Film Comparitive Essay

The Importance of Being Earnest Play/Film Comparative Essay Oliver Parker’s (2002) film adaptation of Oscar Wilde’s play ‘The Importance of Being Earnest’ is sadly completely consumed by the romantic comedy style, masking Wilde’s key concerns and detracting from important comic elements of the play. This can be observed through the varying representations of characters, the film’s lack of contextual jokes, the more prominent sub-plot between Dr Chasuble and Miss Prism, the addition of music and the way in which dialogue, while remaining true to the play, has lost meaning in the film. In the play, Wilde achieves most of his humour through the wonderfully satiric characters, however in the film Parker represents them as being far more†¦show more content†¦In the present context many of Wilde’s contextual jokes in the play may not be as humorous in the present context, thus it is understandable why Parker has placed more emphasis on the farcical jokes, which would appeal to a wider audience. When Wilde wrote the play it was at a time when literature was becoming more widely available for all citizens, wealthy or poor. This gave Wilde room to write as he did, making a mockery of the upper class, as the lower class would enjoy it. However that was over a century ago, and in the modern context people may not find this as relevant or quite as amusing. However, the farcical elements of the play, such as the plot, are the kind of jokes that can be understood in either context. Therefore, Parker has not focused on the contextual jokes, and instead on the fa rcical jokes. It is the farce nature of the plot that Parker has constructed his romantic comedy around. While this enables the film to be appreciated by a wider audience, it no longer embodies Wilde’s criticisms of the upper class, which was the crux of Wilde’s play. However, Parker not only stops at one overembellished farcical plot, but he does the same with an extended sub-plot. In Parker’s film adaptation, his emphasis of the sub-plot between Dr. Chasuble and Miss Prism, while becoming more entertaining, further detracts from Wilde’s concerns and only serves to strengthen the film as a romantic comedy. In Wilde’s play, Chasuble and Prism’s